Volume 21, Number 11—November 2015
Research
Carbapenem-Resistant Enterobacteriaceae in Children, United States, 1999–2012
Table 2
No. (%) isolates analyzed, n = 245,257 | No. (%) CRE isolates analyzed, n = 89 | No. (%) isolates analyzed, n = 63,880 | No. (%) CRE isolates analyzed, n = 171 | ||
---|---|---|---|---|---|
Escherichia coli | 197,807 (80.65) | 27 (29.35) | 36,139 (56.57) | 31 (18.13) | |
Proteus mirabilis | 15,738 (6.42) | 2 (2.17) | 8,747 (13.69) | 56 (32.75) | |
Klebsiella pneumoniae | 14,115 (5.76) | 22 (23.91) | 8,620 (13.49) | 70 (40.94) | |
Enterobacter species† | 8,225 (3.35) | 27 (29.35) | 4,907 (7.68) | 8 (4.68) | |
Serratia marcescens | 4,879 (1.99) | 9 (9.78) | 3,364 (5.27) | 0 | |
Citrobacter species‡ | 4,493 (1.83) | 2 (2.17) | 2,103 (3.29) | 6 (3.51) |
*CRE, carbapenem-resistant Enterobacteriaceae. CRE is defined as resistance to all tested third-generation cephalosporins (ceftriaxone, cefotaxime, or ceftazidime), and nonsusceptiblity to >1 carbapenem (ertapenem, imipenem, meropenem, or doripenem). For bacteria with intrinsic imipenem nonsusceptibility (P. mirabilis), the CRE criteria required nonsusceptibility to >2 of the carbapenems listed. ICU, intensive care unit.
†E. aerogenes and E. cloacae.
‡C. freundii and C. koseri.
Page created: October 29, 2015
Page updated: October 29, 2015
Page reviewed: October 29, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.